Breakers of advanced glycation end products restore large artery properties in experimental diabetes.

B.H.R. Wolffenbuttel; C.M. Boulanger; F.R. Crijns; M.S.P. Huijberts; P. Poiteven; G.N.M. Swennen; S. Vasan; J.J. Egan; A. Cerami; B.I. Levi

doi:10.1073/pnas.95.8.4630

Breakers of advanced glycation end products restore large artery properties in experimental diabetes.

B.H.R. Wolffenbuttel^*, C.M. Boulanger, F.R. Crijns, M.S.P. Huijberts, P. Poiteven, G.N.M. Swennen, S. Vasan, J.J. Egan, A. Cerami, B.I. Levi

^*Corresponding author for this work

NUTRIM School of Nutrition and Translational Research in Metabolism

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Department of Endocrinology, Cardiovascular Research Institute Maastricht and University (Hospital) Maastricht, P.O. Box 5800, 6202 AZ Maastricht, The Netherlands.

Glucose and other reducing sugars react with proteins by a nonenzymatic, posttranslational modification process called nonenzymatic glycation. The formation of advanced glycation end products (AGEs) on connective tissue and matrix components accounts largely for the increase in collagen crosslinking that accompanies normal aging and which occurs at an accelerated rate in diabetes, leading to an increase in arterial stiffness. A new class of AGE crosslink "breakers" reacts with and cleaves these covalent, AGE-derived protein crosslinks. Treatment of rats with streptozotocin-induced diabetes with the AGE-breaker ALT-711 for 1-3 weeks reversed the diabetes-induced increase of large artery stiffness as measured by systemic arterial compliance, aortic impedance, and carotid artery compliance and distensibility. These findings will have considerable implications for the treatment of patients with diabetes-related complications and aging.

Original language	English
Pages (from-to)	4630-4634
Number of pages	5
Journal	Proceedings of the National Academy of Sciences of the United States of America
Volume	95
Issue number	8
DOIs	https://doi.org/10.1073/pnas.95.8.4630
Publication status	Published - 1 Jan 1998

Access to Document

10.1073/pnas.95.8.4630

Cite this

Wolffenbuttel, B. H. R., Boulanger, C. M., Crijns, F. R., Huijberts, M. S. P., Poiteven, P., Swennen, G. N. M., Vasan, S., Egan, J. J., Cerami, A., & Levi, B. I. (1998). Breakers of advanced glycation end products restore large artery properties in experimental diabetes. Proceedings of the National Academy of Sciences of the United States of America, 95(8), 4630-4634. https://doi.org/10.1073/pnas.95.8.4630

@article{4f6cbab9956149a6a20cd05901ccd649,

title = "Breakers of advanced glycation end products restore large artery properties in experimental diabetes.",

abstract = "Department of Endocrinology, Cardiovascular Research Institute Maastricht and University (Hospital) Maastricht, P.O. Box 5800, 6202 AZ Maastricht, The Netherlands.Glucose and other reducing sugars react with proteins by a nonenzymatic, posttranslational modification process called nonenzymatic glycation. The formation of advanced glycation end products (AGEs) on connective tissue and matrix components accounts largely for the increase in collagen crosslinking that accompanies normal aging and which occurs at an accelerated rate in diabetes, leading to an increase in arterial stiffness. A new class of AGE crosslink {"}breakers{"} reacts with and cleaves these covalent, AGE-derived protein crosslinks. Treatment of rats with streptozotocin-induced diabetes with the AGE-breaker ALT-711 for 1-3 weeks reversed the diabetes-induced increase of large artery stiffness as measured by systemic arterial compliance, aortic impedance, and carotid artery compliance and distensibility. These findings will have considerable implications for the treatment of patients with diabetes-related complications and aging.",

author = "B.H.R. Wolffenbuttel and C.M. Boulanger and F.R. Crijns and M.S.P. Huijberts and P. Poiteven and G.N.M. Swennen and S. Vasan and J.J. Egan and A. Cerami and B.I. Levi",

year = "1998",

month = jan,

day = "1",

doi = "10.1073/pnas.95.8.4630",

language = "English",

volume = "95",

pages = "4630--4634",

journal = "Proceedings of the National Academy of Sciences of the United States of America",

issn = "0027-8424",

publisher = "National Academy of Sciences",

number = "8",

}

Wolffenbuttel, BHR, Boulanger, CM, Crijns, FR, Huijberts, MSP, Poiteven, P, Swennen, GNM, Vasan, S, Egan, JJ, Cerami, A & Levi, BI 1998, 'Breakers of advanced glycation end products restore large artery properties in experimental diabetes.', Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 8, pp. 4630-4634. https://doi.org/10.1073/pnas.95.8.4630

Breakers of advanced glycation end products restore large artery properties in experimental diabetes. / Wolffenbuttel, B.H.R.; Boulanger, C.M.; Crijns, F.R. et al.
In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 95, No. 8, 01.01.1998, p. 4630-4634.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Breakers of advanced glycation end products restore large artery properties in experimental diabetes.

AU - Wolffenbuttel, B.H.R.

AU - Boulanger, C.M.

AU - Crijns, F.R.

AU - Huijberts, M.S.P.

AU - Poiteven, P.

AU - Swennen, G.N.M.

AU - Vasan, S.

AU - Egan, J.J.

AU - Cerami, A.

AU - Levi, B.I.

PY - 1998/1/1

Y1 - 1998/1/1

N2 - Department of Endocrinology, Cardiovascular Research Institute Maastricht and University (Hospital) Maastricht, P.O. Box 5800, 6202 AZ Maastricht, The Netherlands.Glucose and other reducing sugars react with proteins by a nonenzymatic, posttranslational modification process called nonenzymatic glycation. The formation of advanced glycation end products (AGEs) on connective tissue and matrix components accounts largely for the increase in collagen crosslinking that accompanies normal aging and which occurs at an accelerated rate in diabetes, leading to an increase in arterial stiffness. A new class of AGE crosslink "breakers" reacts with and cleaves these covalent, AGE-derived protein crosslinks. Treatment of rats with streptozotocin-induced diabetes with the AGE-breaker ALT-711 for 1-3 weeks reversed the diabetes-induced increase of large artery stiffness as measured by systemic arterial compliance, aortic impedance, and carotid artery compliance and distensibility. These findings will have considerable implications for the treatment of patients with diabetes-related complications and aging.

AB - Department of Endocrinology, Cardiovascular Research Institute Maastricht and University (Hospital) Maastricht, P.O. Box 5800, 6202 AZ Maastricht, The Netherlands.Glucose and other reducing sugars react with proteins by a nonenzymatic, posttranslational modification process called nonenzymatic glycation. The formation of advanced glycation end products (AGEs) on connective tissue and matrix components accounts largely for the increase in collagen crosslinking that accompanies normal aging and which occurs at an accelerated rate in diabetes, leading to an increase in arterial stiffness. A new class of AGE crosslink "breakers" reacts with and cleaves these covalent, AGE-derived protein crosslinks. Treatment of rats with streptozotocin-induced diabetes with the AGE-breaker ALT-711 for 1-3 weeks reversed the diabetes-induced increase of large artery stiffness as measured by systemic arterial compliance, aortic impedance, and carotid artery compliance and distensibility. These findings will have considerable implications for the treatment of patients with diabetes-related complications and aging.

U2 - 10.1073/pnas.95.8.4630

DO - 10.1073/pnas.95.8.4630

M3 - Article

SN - 0027-8424

VL - 95

SP - 4630

EP - 4634

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

IS - 8

ER -